Nanosonics Limited · ASX:NAN
Nanosonics — Shareholder Meeting (November 2026)
43 slides from Nanosonics's shareholder meeting presentation, Nov 4, 2026
Slide 1: From a proven product, to a multi-platform leader
Dra v4 r personal use only From a proven product, to a multi-pla orm leader. Annual General Meeting 2026 4 November 2026
Slide 2: A strongly independent Board with diverse skills
r personal use only A strongly independent Board with diverse skills Steven Sargent BBus, Michael Kavanagh BSc, Marie McDonald BSc Larry Marshall BSc (Hons), FAICD, FTSE MBA (Advanced) (Hons), LLB (Hons), FAICD PhD, FAICD, FTSE, FAIP, Independent Non-executive CEO, President and Independent Non-exec
Slide 3: How to ask a question
r personal use only How to ask a question • To ask a wri en question, select the Q & A icon. • Select the topic your question relates to from the drop-down list. • Type your question in the text box and press the send icon. • To ask a verbal question follow the instructions below the broadcast windo
Slide 4: How to vote
r personal use only How to vote • When the poll is open, select the vote icon at the top of the screen • To vote, select either For, Against or Abstain • You will see a vote confirmation • To change or cancel your vote “click here to change your vote” at any time until the poll is closed 4
Slide 5: Steve Sargent, Non-executive Director and Chairman
r personal use only Steve Sargent Non-executive Director and Chairman 5
Slide 6: Our focus is infection prevention, for life
r personal use only Our focus is infection prevention, for life Our mission is to improve the safety of patients, clinics, their staff and the environment by transforming the way infection prevention practices are understood and conducted by introducing innovative technologies that deliver improved s
Slide 7: Evolving infection prevention environment
r personal use only Evolving infection prevention environment Leveraging its expertise in automation, medical reprocessing and digitisation, Nanosonics is leading the way to support healthcare providers to protect more patients. INFECTION PREVENTION DYNAMICS Technology advancements Safer for patient
Slide 8: Driving value creation
r personal use only Driving value creation Nanosonics is entering a defining period of growth trophon business Creates opportunities model & performance for tomorrow Growing revenue & EBIT in constant currency Product growth & expansion Disciplined capital allocation CORIS Improving operating leverag
Slide 9: Our commitment to sustainability
r personal use only Our commitment to sustainability Caring for our customers and their patients, our partners, our people, the planet and the community. Five areas of focus reduction in Scope 1 and 2 emissions in FY26 80% reduction over the past 2 years 9
Slide 10: A strongly independent Board with diverse skills
r personal use only A strongly independent Board with diverse skills Steven Sargent BBus, Michael Kavanagh BSc, Marie McDonald BSc Larry Marshall BSc (Hons), FAICD, FTSE MBA (Advanced) (Hons), LLB (Hons), FAICD PhD, FAICD, FTSE, FAIP, Independent Non-executive CEO, President and Independent Non-exec
Slide 11: Newly announced independent Non-executive Board member
r personal use only Newly announced independent Non-executive Board member Julien Sauvagnargues Independent Non-executive Director Joining the Nanosonics Board on 1 December 2026 • Global MedTech executive • Two decades at Olympus • European and North American experience • Commercial, growth and ope
Slide 12: Building the future of automated infection prevention
r personal use only Building the future of automated infection prevention Michael Kavanagh CEO, President and Managing Director 12
Slide 13: Led by an experienced team
r personal use only Led by an experienced team Michael Kavanagh BSc, MBA Jason Burriss BCom, CA Kimberly Hill BSc Rod Lopez MBA, BEng (Hons), Ma hew Carbines LLB, Jodi Sampson MBA(Exec), (Advanced) GAICD Bcom CPHR, MAICD Chief Financial Officer Chief Marketing Officer & CEO, President and Managing Regio
Slide 14: FY26: underlying growth, disciplined execution
r personal use only FY26: underlying growth, disciplined execution A strong core business continued to fund investment in the next pla orm. $203.9m $211.5m 76.9% $21.6m $155.2m reported revenue revenue at CC gross margin EBIT at CC cash 3% growth 6% growth 77.6% at CC 21% growth no debt Core franchi
Slide 15: Core trophon-only business profitability growing strongly
r personal use only Core trophon-only business profitability growing strongly Generating cash and funding next pla orm growth. Sustained EBIT growth and high-quality cash conversion in the trophon-only business demonstrates durability and provides self- funded capacity for the next phase of growth. E
Slide 16: FY26 delivery positioned Nanosonics for its next phase
r personal use only FY26 delivery positioned Nanosonics for its next phase Disciplined operational execution laid the foundations for the next phase of growth TROPHON CORIS OPERATIONS DIGITAL trophon3 and trophon2 Clearances across US consumables Connectivity and Plus launched; Australia, Europe and
Slide 17: Nanosonics reaffirms FY27 guidance
r personal use only Nanosonics reaffirms FY27 guidance Q1 FY27 performance is consistent with Nanosonics’ expectations. FY27 guidance at constant currency $220 million to $228 million, Revenue reflecting 8% to 12% growth on FY26. Gross Profit % 74%-76% Operational $156 million to $163 million, expenses
Slide 18: From a successful single-platform company to a repeatable platform company
r personal use only From a successful single-pla orm company to a repeatable pla orm company Repeat our capability selectively. Scale FUTURE CORIS. PLATFORMS Build CORIS from trophon. SECOND PLATFORM trophon PROVEN CORE 18
Slide 19: The opportunity is to automate what healthcare still performs manually
r personal use only The opportunity is to automate what healthcare still performs manually Manual variability, fragmented records and workforce pressure create a broad class of problems to solve. Replace technique-dependent work with AUTOMATE automated workflows Deliver repeatable performance across
Slide 20: The capability system to deliver our growth strategy
r personal use only The capability R&D + engineering - Pla orm, product, so ware and consumables system to Clinical + medical – deliver our Need definition, evidence and adoption growth strategy Bioscience – biological models and testing Regulatory + quality - Global clearances and validated systems
Slide 21: trophon still has a substantial runway for profitable growth
r personal use only trophon still has a substantial runway for profitable growth The pla orm can compound through installed base, upgrades, utilisation and lifetime value. 39,230 8,000 $149.2m $50.6m installed base EPR upgrade opportunity recurring revenue trophon-only EBIT 6% FY26 growth remaining i
Slide 22: Nanosonics CORIS System
r personal use only Nanosonics CORIS® System. A new era in flexible endoscope reprocessing starts here.
Slide 23: A critical cleaning step, manual methods cannot reliably complete
A critical cleaning step, r personal use only manual methods cannot reliably complete Cleaning is the critical first step in reprocessing flexible endoscopes, yet it remains manual, variable and unverified. The CORIS System automates it. THE PROBLEM THE SOLUTION Manual cleaning cannot reach every chann
Slide 24: Large CORIS recurring revenue opportunity
r personal use only Large CORIS recurring revenue opportunity Capital, consumables and service compound as the installed base grows, leveraging the same annuity model as trophon. FY27 launch markets CAPITAL & ACCESSORIES UTILISATION UNITED KINGDOM & IRELAND 3-5X TROPHON ~10 capital price cycles per
Slide 25: r personal use only
r personal use only 25
Slide 26: The CORIS System is delivering a consistently positive staff experience
r personal use only The CORIS System is delivering a consistently positive staff experience UK CMR site feedback highlights strong workflow, usability and confidence in routine adoption OVERALL RESULT • Reduced hands-on manual cleaning Workflow & • Staff time can be redirected 4.65 / 5 capacity • Smoothe
Slide 27: UK & Ireland CORIS launch
r personal use only UK & Ireland CORIS launch Manchester Science & Industry Museum 27
Slide 28: Medical & Scientific category
r personal use only ® Medical & Scientific category
Slide 29: The Nanosonics vision
r personal use only THE NANOSONICS VISION A multi-pla orm leader in automated infection prevention Build Scale Expand from CORIS trophon’s proven franchise and to redefine endoscope the por olio and geographic continuing growth reprocessing globally reach with discipline Building on trophon’s success
Slide 30: r personal use only
r personal use only 30
Slide 31: Election of a Director, Ms Sarah Butler
r personal use only Election of a Director, Ms Sarah Butler Sarah Butler FAICD Independent Non-executive Director To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That Ms Sarah Butler, who was appointed as a Director by the Board on 20 January 2026 and reti
Slide 32: Re-election of a Director, Dr Larry Marshall
r personal use only Re-election of a Director, Dr Larry Marshall Larry Marshall BSc (Hons), PhD, FAICD, FTSE, FAIP, Federation Fellow Independent Non-executive Director To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That Dr Larry Marshall, who retires as
Slide 33: Re-election of a Director, Dr Tracey Batten
r personal use only Re-election of a Director, Dr Tracey Ba en Tracey Ba en MBBS, MBA (Harvard), FAICD, MHA, FRACMA Independent Non-executive Director To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That Dr Tracey Ba en, who retires as a Director by rotati
Slide 34: Adoption of Remuneration Report
r personal use only Adoption of Remuneration Report To consider and, if thought fit, to pass the following advisory, non-binding resolution (in accordance with section 250R(3) of the Corporations Act) as an ordinary resolution: That, for the purposes of section 250R(2) of the Corporations Act and for
Slide 35: Issue of 70,833 Service Rights to the CEO
r personal use only Issue of 70,833 Service Rights to the Chief Executive Officer and President, Mr Michael Kavanagh, in respect of Mr Kavanagh’s 2026 Short Term Incentive grant (FY26 STI) and under the Nanosonics Equity Plan To consider and, if thought fit, to pass the following resolution as an ordin
Slide 36: Issue of 625,363 Performance Rights to the CEO
r personal use only Resolution 6 Issue of 625,363 Performance Rights to the Chief Executive Officer and President, Mr Michael Kavanagh, in respect of Mr Kavanagh’s FY27 Long- Term Incentive grant (FY27 LTI) and under the Nanosonics Equity Plan To consider and, if thought fit, to pass the following reso
Slide 37: Approval of the Nanosonics Equity Plan
r personal use only Resolution 7 Approval of the Nanosonics Equity Plan To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That, for the purpose of ASX Listing Rule 7.2 (Exception 13) and for all other purposes, the Nanosonics Equity Plan (the terms and condi
Slide 38: Increase in maximum aggregate Non-Executive Directors' Remuneration
r personal use only Increase in maximum aggregate Non- Executive Directors’ Remuneration To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That, for the purposes of clauses 22.1 and 22.8 of the Company’s Constitution and ASX Listing Rule 10.17 (and for all o
Slide 39: How to ask a question
r personal use only How to ask a question • To ask a wri en question, select the Q & A icon. • Select the topic your question relates to from the drop-down list. • Type your question in the text box and press the send icon. • To ask a verbal question follow the instructions below the broadcast windo
Slide 40: How to vote
r personal use only How to vote • When the poll is open, select the vote icon at the top of the screen • To vote, select either For, Against or Abstain • You will see a vote confirmation • To change or cancel your vote “click here to change your vote” at any time until the poll is closed 40
Slide 41: How to ask a question
r personal use only How to ask a question • To ask a wri en question, select the Q & A icon. • Select the topic your question relates to from the drop-down list. • Type your question in the text box and press the send icon. • To ask a verbal question follow the instructions below the broadcast windo
Slide 42: Thank you
r personal use only Thank you Nanosonics Limited 7-11 Talavera Road Macquarie Park, NSW 2113 Australia T +61 2 8063 1600 E info@nanosonics.com.au www.nanosonics.com.au ABN 11 095 076 896
Slide 43: Disclaimer
r personal use only Disclaimer This presentation is intended to provide a general The information does not constitute advice of any Subject to any continuing obligations under outline only and is not intended to be a definitive kind and should not be relied on as such. Investors applicable law or any